Angie Wirick

“Yeah, so the company was founded really focused on treating patients who are undergoing cardiac surgery, treating their AFib. So you're going into cardiac surgery and you already have pre-existing AFib diagnosis.”

“Third quarter worldwide revenue was $154.5 million, increasing 15% on a reported basis and 15.1% in constant currency compared with the third quarter of 2025. This strong performance was powered by growth across our pain management, open ablation, and appendage management franchises.”

“Yeah, I think it's easy to say both on top line and bottom line ahead of where we thought we would be relative to the LRP targets. I think first and foremost, we step back, we put the LRP targets out there.”

“We are ahead of our LRP relative to the bottom line expectations. And I think we feel comfortable that we can continue to improve profitability, improve margins, continue to generate cash flow.”

“Our third quarter 2023 worldwide revenue of $98.3 million increased 18.1% on a reported basis and 17.3% on a constant currency basis when compared to the third quarter of 2022, reflecting continued strong performance of our business globally and contribution across our broad portfolio of products.”